Javle M, Shacham-Shmueli E, Xiao L, et al. - This study attempted to explore the therapeutic effectiveness of the poly–(adenosine diphosphate–ripose) polymerase (PARP) inhibitor olaparib for patients with pancreatic cancer with BRCAness. Researchers conducted two parallel phases 2 nonrandomized clinical trials to ascertain the effectiveness of olaparib as monotherapy in advanced, previously treated pancreatic ductal adenocarcinoma cancer (PDAC) with BRCAness from November 11, 2016, to October 2, 2018, among 46 patients in Israel and Texas. A total of 48 patients were included, and 46 (26 women [57%]; mean [SD] age, 65.5 [11.1] years) were evaluable. In PDAC, the definition of the BRCAness phenotype may be limited to patients harboring DNA damage repair genetic alterations (DDR-GAs). These 2 phase 2 nonrandomized clinical trials demonstrated that olaparib was well tolerated and indicated limited antitumor activity in patients with advanced, platinum-sensitive PDAC with DDR-GAs. These findings imply a potential therapeutic opportunity for a subset of patients with PDAC.